HealthRegeneron weight-loss drug halves muscle loss when combined with Novo's semaglutide in trial
In a study of patients with obesity, Regeneron’s experimental weight-loss drug cut muscle-mass loss by 50% when used with Novo Nordisk’s semaglutide, compared with semaglutide alone. The data are due to be presented at a medical meeting.
R
Reuters★★☆☆☆2026-09-30 22:45Original
Regeneron weight-loss drug halves muscle loss when combined with Novo's semaglutide in trial
Health